

In the Claims

1-10. (canceled)

11. (previously presented) A method for the treatment of liver fibrotic inflammatory and/or liver autoimmune diseases comprising the administration of an effective amount of a CC-chemokine mutant having reduced GAG-binding activity, wherein the CC-chemokine is CCL3 / MIP-1alpha, CCL4 / MIP-1beta, or CCL5 / RANTES.

12. (previously presented) The method according to claim 11, wherein the CC-chemokine is CCL5 / RANTES and the mutant is triple 40's RANTES mutant (SEQ ID NO: 1).

13. (previously presented) The method according to claim 11, wherein the CC-chemokine is CCL3 / MIP-1alpha and the mutant is triple MIP-1alpha mutant (SEQ ID NO: 2).

14. (previously presented) The method according to claim 11, wherein the CC-chemokine is CCL4 / MIP-1beta and the mutant is triple MIP-1beta mutant (SEQ ID NO: 3).

15. (previously presented) The method according to claim 11, wherein the CC-chemokine mutant is an active variant of said CC-chemokine mutant in which one or more amino acids have been inserted, deleted, or substituted in a conservative manner.

16. (previously presented) The method according to claim 12, wherein the CC-chemokine mutant is an active variant of said CC-chemokine mutant in which one or more amino acids have been inserted, deleted, or substituted in a conservative manner.

17. (previously presented) The method according to claim 13, wherein the CC-chemokine mutant is an active variant of said CC-chemokine mutant in which one or more amino acids have been inserted, deleted, or substituted in a conservative manner.

18. (previously presented) The method according to claim 14, wherein the CC-chemokine mutant is an active variant of said CC-chemokine mutant in which one or more amino acids have been inserted, deleted, or substituted in a conservative manner.

19. (canceled)

20. (previously presented) The method according to claim 11, wherein the CC-chemokine mutant further comprises an amino acid sequence belonging to a protein sequence other than the corresponding CC-chemokine.

21. (previously presented) The method according to claim 11, wherein the CC-chemokine mutant is in the form of an active precursor, salt, derivative, conjugate or complex.

22. (previously presented) The method according to claim 11, wherein the liver disease is an alcoholic liver disease, a viral hepatitis, or an autoimmune hepatitis.